Mutagenicity of organophosphorus compounds in bacteria and drosophila

140 Organophosphorus compounds (OP's) have been tested for mutagenic activity in bacteria, principally by using two specially constructed sets of tester strains of the bacteria Salmonella typhimurium and Escherichia coli. It was found that 20% gave positive mutagenic responses and that this group of chemicals produce base substitutions rather than frame-shift mutations. In most cases the DNA repair genes exrA⁺ and recA⁺ were for mutagenic activity.Seven compounds were further tested in Drosophila melanogaster for the ability to induce recessive lethal mutations. In some of these cases the doses administered to the flies had to be very low due to the highly toxic nature of the compounds. To overcome this problem, the accumulation of recessive lethal mutations was measured in populations which were continually exposed to the compounds over a period of some 18 months. During this time the populations developed increased resistance to the compound and so the dose administered could gradually be increased. Six of the compounds were mutagenic.Of the compounds tested in both systems, those showing mutagenic activity in bacteria were also mutaganic in Drosophila, those mutagenic in bacteria were not mutagenic in Drosophila.     

腹股沟疝腹腔镜下修补术与无张力修补术应用于老年患者的综合疗效研究

目的:腹股沟疝是外科中最常见的疾病之一,手术治疗是腹股沟疝的惟一可靠方法。腹腔镜下腹股沟疝修补术,尤其是完全腹膜外腹腔镜(Totally Extra-preperioneal Prosthetic,TEP)疝修补术,已经成为腹股沟疝治疗的"金标准"。然而,针对65岁以上老年人群,心血管基础疾病较多,全麻风险大,TEP术式疗效是否优于无张力疝修补术还未有报道,本研究拟探讨针对老年人腹股沟疝修补的最佳手术方式。方法:排除两种修补术明确的禁忌症患者,对研究入组的92例≥65岁腹股沟疝老年患者,根据手术方式(TEP术或无张力疝修补术)进行分组,术后分别统计:(1)围手术期评价指标(手术时间、术中出血量、手术并发症、疼痛等级、离床活动时间、住院时间及住院总费用);(2)远期随访指标(术后2年内的慢性疼痛和复发情况)。综合评估腹腔镜下修补术与无张力修补术应用于老年腹股沟疝气治疗的综合疗效。结果:TEP术相比于无张力疝术只显示出在平均减少20 m L出血量及缓解术后24小时1个AVS疼痛数量级的优势(P0.01);在术后下床活动时间、手术时间、术后96小时疼痛指数、围手术期并发症、住院天数、慢性疼痛指数及远期疗效等主要评价指标中均与无张力修补术相当(P0.05);但却大大增加了手术费用(P0.01)。结论:针对≥65岁腹股沟疝老年患者,尤其是基础疾病多,对医疗费用敏感的人群,开展无张力修补术仍不失为目前最佳选择。     

Bilan initial d’imagerie de l’adénocarcinome pancréatique : données de la littérature sur la place actuelle de la tomographie par émission de positons au 18F-fluorodéoxyglucose (TEP FDG)

In pancreatic adenocarcinoma, initial imaging is essential to better select patients for surgery. Recent literature analysis of F18-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET) in pancreatic adenocarcinoma is summarized in the present article. Performances of FDG PET in the fields of lymph node involvement, metastatic involvement and therapeutic efficacy assessment are described for its correct use in pancreatic adenocarcinoma.     

Does Phaeocystis spp. contribute significantly to vertical export of organic carbon?

Phaeocystis spp. cell and colony mass fluxes and their contribution to the vertical particulate organic carbon (POC) export from a wide range of stations were quantified by short-term sediment traps. The compilation of available data, ranging from polar to sub-arctic and boreal regions, revealed that Phaeocystis colonial and single cells frequently are observed in shallow sediment traps at 30–50 m depth (average of 7 ± 11% of POC export). A strong vertical export decline between 40 m and 100 m diminished the contribution of Phaeocystis spp. cell carbon to vertical export of POC to only 3 ± 2% at 100 m depth, with two exceptions (deeper mixed stations). Estimates of potential corresponding mucus contribution increased the average Phaeocystis spp. contribution to <5% of POC export. The vertical flux attenuation efficiency is higher for Phaeocystis spp. than for diatoms. The overall contribution of Phaeocystis spp. to vertical carbon export based on direct investigations of vertical organic carbon export is small.     

Évaluation de la réponse au traitement du lymphome avec la TEP F-FDG : existe-t-il un consensus dans l’évaluation de la réponse ?

The concept of risk-adapted therapy in lymphoma is increasingly accepted as a way to achieve higher cure rates with a lower or equal risk of treatment-related morbidity and mortality. Tailoring and individualizing therapy according to the need of the patient is a therapeutic option which could maybe soon become the standard of care. However, it is still not proven that modifying therapy based on interim-PET can improve patient outcomes. Therefore, this issue must be analyzed in appropriately designed clinical trials. ¹⁸F-FDG PET enables evaluation of the early metabolic changes rather than the morphologic changes which occur later during therapy. In lymphoma these early metabolic changes are highly predictive of the final treatment response. PET performed after a few courses of standard chemotherapy is a reliable prognostic tool to identify poor responders to therapy. Interim-PET is a powerful prognostic tool when compared to other well-established clinical parameters in lymphoma. However, the major drawback in the literature appeared to be related to the lack of uniform and reliable criteria for interim-PET scan interpretation. Therefore, in April 2009 an international meeting took place in Deauville (France), where uniform criteria were established for interim-PET scan interpretation. On the other hand, when PET is used to assess treatment response after completion of therapy, the criteria established in the International Harmonization Project in 2007 must be applied. These recommendations were designed to standardize the interpretation of interim PET and PET at the conclusion of therapy of patients with lymphoma both in clinical practice and clinical trials.     

Comparaison de la dose efficace en TEP/TDM et en TDM

Hybrid imaging, particularly positron emission tomography (PET) combined with CT has emerged in the field of oncology as a modality of choice. The concomitant realization of a standard CT examination, however, raises the question of the additional dose delivered to the patient. This radiation burden could be avoided by performing a single PET/CT examination with injection of contrast media. To verify the potential dosimetric gain of this strategy, we compared the effective dose associated with each modality in a retrospective cohort of 151 patients, homogeneous in weight and size. The average effective dose for a PET/CT (injection of 5-6 MBq/kg of ¹⁸FDG) was 13.5 mSv, the CT dose representing approximately 80% of the PET dose. In our study, the average effective dose in CT thorax/abdomen/pelvis was 21.4 mSv, 60% higher than the PET/CT effective dose.     

TEP/TDM dans le diagnostic et la stadification des lymphomes

Histological subtypes of lymphomas are important because FDG uptake is much greater in aggressive than in indolent lymphomas and this, results in lower sensitivity of PET for the staging of indolent lymphomas. Staging is especially useful when treatment is changed according to staging. Staging with imaging methods has traditionally been performed using a CT scanner and has been based on the detection of nodal enlargement, an increased number of small nodes and in the presence of extranodal masses. However, CT is limited by its poor sensitivity in the detection of extranodal sites of involvement, in the identification of tumour involvement of normal size lymph nodes and in the differentiation between malignant and inflammatory enlarged lymph nodes. The uptake of FDG detected with PET images reflects metabolic activity rather than the size of the tissue masses, localizing tumoral activity in enlarged and in normal size lymph nodes. In the literature review that compares PET with CT, PET usually indicates more lesions than CT would and PET improves sensitivity without losing specificity. However, the majority of studies report that PET, improves the staging in a relatively limited number of patients (10-20%) and may change treatment in less than 10% of patients. Diagnostic accuracy of PET may improve with the use of hybrid PET/CT systems that combine metabolic and morphological imaging, in the same scanner and without moving the patient. This is a promising technique that will overcome the limitations of both modalities and may enhance diagnostic accuracy in lymphoma patients. This hybrid equipment allows the use of PET/CT with contrast-enhanced full dose CT (a diagnostic CT) instead of carrying out PET and CT on different days.     

Intérêt de la TEP/TDM au FDG dans l’investigation étiologique des syndromes paranéoplasiques

Paraneoplastic syndromes (PNS) represent a rare and heterogeneous group of entities whose clinical symptoms may sometimes antedate the diagnosis of the causative tumor. In the context, the identification of the underlying tumor becomes very important for the patient's functional and sometimes vital prognosis, by allowing an earliest treatment of the tumor. ¹⁸FDG PET/CT has become indispensable in the diagnosis and follow-up of numerous cancers but its role in etiological investigation of isolated paraneoplastic syndromes for the research of an occult tumor is not defined yet. Nevertheless, requests of PET/CT in this indication are frequent in nuclear medicine departments, with an uncertain diagnostic yield. We have listed retrospectively 64 patients, sent to nuclear medicine department of Nancy university hospital between 2004 and 2010 for the research of an occult tumor because of a clinically suspected paraneoplastic syndrome, in order to estimate its diagnostic contribution in this indication. According to our results, ¹⁸FDG PET-CT would be interesting by its negative predictive value concerning the tumoral risk, in keeping with its known sensitivity PET-CT may also present an interest for the diagnosis and the characterization of non-tumoral conditions generating symptoms initially wrongly suspected to be paraneoplastic.